Market capitalization | $98.25b |
Enterprise Value | $136.18b |
P/E (TTM) P/E ratio | 18.15 |
EV/FCF (TTM) EV/FCF | 10.41 |
EV/Sales (TTM) EV/Sales | 2.86 |
P/S ratio (TTM) P/S ratio | 2.06 |
P/B ratio (TTM) P/B ratio | 5.65 |
Dividend yield | 5.01% |
Last dividend (FY24) | $2.42 |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
28 Analysts have issued a Bristol-Myers Squibb forecast:
28 Analysts have issued a Bristol-Myers Squibb forecast:
Mar '25 |
+/-
%
|
||
Revenue | 47,636 47,636 |
5%
5%
|
|
Gross Profit | 35,579 35,579 |
3%
3%
|
|
EBITDA | 20,261 20,261 |
3%
3%
|
EBIT (Operating Income) EBIT | 12,916 12,916 |
23%
23%
|
Net Profit | 5,419 5,419 |
188%
188%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
Head office | United States |
CEO | Christopher Boerner |
Employees | 34,100 |
Founded | 1933 |
Website | www.bms.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.